Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Medtronic has seen one of the most dramatic short-side reconfigurations in the large-cap medical device space this week: a position that was negligible six weeks ago has grown to nearly 9.5% of free float, and the borrow market has swung from abundant to genuinely expensive in a single session.
The story since the last note on October 7 is how much has changed. At that point, short interest had doubled to around 37.5 million shares, availability was vast, and cost to borrow was near its lowest levels of the quarter. All three of those statements are now out of date. Short interest climbed further to a peak of 129 million shares on October 9 before pulling back slightly to 119.5 million on October 13, a level that represents 9.3% of free float. To put that in context, the position was 17.4 million shares on September 30 and 14.3 million in early September. This is not a gradual accumulation; it is a structural repositioning compressed into less than three weeks. The ORTEX short score has followed: it reached 73.6 on October 9, up from 29.8 on September 30, marking a complete reversal from a stock that had been sitting comfortably below the 31st percentile for most of the past month.
The borrow market has tightened sharply to match. Cost to borrow closed at 18.5% on October 13, up from 0.67% the session before and 0.51% a week earlier, a roughly 30-fold move in a single day. For a stock of Medtronic's size and institutional depth, that is an arresting number. Availability has also compressed: with shares available equivalent to roughly 112% of short interest, the pool is no longer abundant. That compares with availability of over 900% in early October and readings that were effectively uncapped through most of September. The lending pool is not yet constrained enough to force covering, but the direction is clear. Options tell a calmer story. The put/call ratio is 0.70, only slightly above its 20-day average of 0.66, and well within the normal range. The spike to 0.93 seen on October 7 and 8 has not persisted, suggesting options traders have not materially added to the defensive tilt that briefly appeared.
The Street remains broadly constructive, and recent analyst activity has leaned bullish despite the short-side pressure. Following the September 1 earnings release, multiple firms lifted targets: BofA raised its objective to $110 from $95, UBS moved to $110 from $100, and TD Cowen reiterated a Buy with a $110 target. Barclays initiated coverage at Equal-Weight with a $95 target on October 7, and BTIG trimmed its target modestly to $99 from $100 while keeping a Buy rating on October 12. The consensus mean target is $104.40 against a current price of $93.01, implying roughly 12% upside. Bulls point to the Affera/Sphere-9 pulsed-field ablation platform, which posted 88% worldwide growth in the first quarter, with management projecting the business will expand at 2.5 times the broader electrophysiology market rate in FY27. Bears lean on the deceleration embedded in guidance, with organic revenue expected to slow from 6.5% in the first half to 5.4% in the second, a $200 million net tariff expense biting into margins, and ongoing weakness in Structural Heart and Neuromodulation.
The two most recent earnings reactions both came in positive: the August print produced a 3.9% one-day gain and modest five-day follow-through, and the September release added 1.7% on the day. The next event is scheduled for November 24, which means the current short build is arriving more than six weeks ahead of the print, suggesting this is not purely an earnings hedge. Franklin Templeton added nearly 3.9 million shares in the most recent reported period, and BlackRock increased its position by nearly 3 million shares, providing some institutional counterweight to the short side.
With short interest now at its highest level in the observable window, cost to borrow having spiked and availability tightening meaningfully, the dynamic heading into November earnings is less about whether shorts are present and more about whether the lending market can absorb further position growth without pushing borrow costs to levels that force involuntary covering.
See the live data behind this article on ORTEX.
Open MDT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
